PASITHEA THERAPEUTICS CORP. Amortization
PASITHEA THERAPEUTICS CORP. (KTTA) reported Amortization of $315.08 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2026-08-14
- PASITHEA THERAPEUTICS CORP. amortization for the quarter ending 2026-06-30 was $157.54K, a 0.00% change year-over-year.
- PASITHEA THERAPEUTICS CORP. amortization for the quarter ending 2026-03-31 was $157.54K, a 0.00% change year-over-year.
- PASITHEA THERAPEUTICS CORP. amortization for the quarter ending 2025-12-31 was $157.54K, a 0.00% change year-over-year.
- PASITHEA THERAPEUTICS CORP. amortization for the quarter ending 2025-09-30 was $157.54K, a 0.00% change year-over-year.
- PASITHEA THERAPEUTICS CORP. amortization for fiscal 2025 was $630.16K, a 0.00% change from fiscal 2024.
- PASITHEA THERAPEUTICS CORP. amortization for fiscal 2024 was $630.16K, a 0.00% change from fiscal 2023.
- PASITHEA THERAPEUTICS CORP. amortization for fiscal 2023 was $630.16K.
| Period end | Amortization 3 month | Amortization 6 month | Amortization 9 month | Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $157.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $315.08K 10-Q · filed 2026-08-14 | $472.62K derived: sum of 3 quarters · filed 2026-08-14 | $630.16K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $157.54K 10-Q · filed 2026-05-15 | $315.08K derived: sum of 2 quarters · filed 2026-05-15 | $472.62K derived: sum of 3 quarters · filed 2026-05-15 | $630.16K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $157.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $315.08K derived: sum of 2 quarters · filed 2026-03-30 | $472.62K derived: sum of 3 quarters · filed 2026-08-14 | $630.16K 10-K · filed 2026-03-30 |
| 2025-09-30 | $157.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $315.08K derived: sum of 2 quarters · filed 2026-08-14 | $472.62K 10-Q · filed 2025-11-13 | $630.16K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $157.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $315.08K 10-Q · filed 2026-08-14 | $472.62K derived: sum of 3 quarters · filed 2026-08-14 | $630.16K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $157.54K 10-Q · filed 2026-05-15 | $315.08K derived: sum of 2 quarters · filed 2026-05-15 | $472.62K derived: sum of 3 quarters · filed 2026-05-15 | $630.16K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $157.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $315.08K derived: sum of 2 quarters · filed 2026-03-30 | $472.62K derived: sum of 3 quarters · filed 2026-03-30 | $630.16K 10-K · filed 2026-03-30 |
| 2024-09-30 | $157.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $315.08K derived: sum of 2 quarters · filed 2025-11-13 | $472.62K 10-Q · filed 2025-11-13 | $630.16K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $157.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $315.08K 10-Q · filed 2025-08-14 | $472.62K derived: sum of 3 quarters · filed 2025-08-14 | $630.16K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $157.54K 10-Q · filed 2025-05-15 | $315.08K derived: sum of 2 quarters · filed 2025-05-15 | $472.62K derived: sum of 3 quarters · filed 2025-05-15 | $630.16K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $157.54K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $315.08K derived: sum of 2 quarters · filed 2025-03-24 | $472.62K derived: sum of 3 quarters · filed 2025-03-24 | $630.16K 10-K · filed 2025-03-24 |
| 2023-09-30 | $157.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $315.08K derived: sum of 2 quarters · filed 2024-11-13 | $472.62K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $157.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $315.08K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $157.54K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |